The Food and Drug Administration authorized Novavax's single-strain vaccine, which targets omicron subvariant XBB.1.5, for emergency use in people ages 12 and up. The Centers for Disease Control and ...
Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on a diversified non-COVID portfolio and a fresh push into obesity drugs.
Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...
The Food and Drug Administration announced Thursday it has greenlighted updated COVID-19 vaccines from Pfizer and Moderna for the 2024 fall season. The decision clears the way for distribution to ...
1mon
Moderna Vaccine
Read Moderna Vaccine latest news on The Economic Times. Moderna Vaccine updates, Moderna Vaccine videos & more.
An infectious disease expert has dismissed calls for more COVID vaccine makers to withdraw their jabs. Here’s why.
Stocktwits on MSN
NVAX stock eyes breakout week: Novavax claims patients were ‘twice as likely’ to pick its COVID shot over Moderna again
Novavax posted Q1 revenue of $139.5 million, above analysts’ estimate of $78.3 million, helped by licensing agreements. ・The drugmaker also said that patients who received Nuvaxovid were “twice as ...
Pfizer (PFE) posted Q4 adjusted EPS of $0.66 beating the $0.57 consensus on $17.56B in revenue while its non-COVID portfolio grew 9% operationally, led by Abrysvo (+136%) and Lorbrena (+45%), plus a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results